Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
The Aprotinin Story — Is BART the Final Chapter?
50
Zitationen
2
Autoren
2008
Jahr
Abstract
The aprotinin story began in 1987, when investigators reported that the use of the drug in patients undergoing repeat open-heart surgery decreased the need for blood transfusion by a factor of 8.1 In 1993, the Food and Drug Administration (FDA) approved the use of aprotinin to reduce blood loss during coronary-artery bypass grafting, and the drug became widely used in cardiac surgery. In 2006, the use of aprotinin became controversial when the drug was associated with an increased risk of renal failure, myocardial infarction, stroke, and death in a large observational study.2,3 Two subsequent cohort studies also linked aprotinin . . .
Ähnliche Arbeiten
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
1999 · 5.187 Zit.
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial
2010 · 3.211 Zit.
Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma
2015 · 2.396 Zit.
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
1999 · 2.044 Zit.
Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin
1987 · 2.019 Zit.